Research progress in the treatment of cardiovascular diseases with extracellular vesicles

Zhaoyang Jiang

doi:10.62051/hwfcsp73

Authors

Zhaoyang Jiang

DOI:

https://doi.org/10.62051/hwfcsp73

Keywords:

Extracellular vesicles; cardiovascular diseases; non cellular therapy.

Abstract

Extracellular vehicles (EVs) are small lipid vesicles that can release signaling substances containing proteins, nucleic acids, and other bioactive molecules. Recent research shows that EVs have potential application prospects in the treatment of cardiovascular diseases. EVs can alter the function of damaged cells and promote the repair and regeneration of cardiovascular tissue by transmitting bioactive molecules. In addition, EVs have the characteristics of low immunogenicity and high stability, making it a potential therapeutic strategy for cardiovascular diseases. Although the current research is still in the pre-clinical stage, with the further revelation of the mechanism of cardiovascular disease treatment using EVs, the treatment of cardiovascular diseases by EVs is bound to enter the clinical stage. This review expounds the advantages of EVs in cardiovascular diseases, and systematically lists the current application progress of EVs in a variety of cardiovascular diseases.

Downloads

Download data is not yet available.

References

Yu N, Cong LC, Zhang ZC. Molecular and cell-based therapy of ischemic heart disease [J]. Chinese Journal of Cardiovascular Medicine, 2005, 10 (5): 388 - 390. DOI: 10.3969/j.issn.1007-5410. 2005. 05. 026.

Luo RJ, Ai XF, Li KX, et al. Transplantation of human induced pluripotent stem cell derived cardiac progenitor cells for acute myocardial infarc-tion in rats. [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19 (3): 213 - 222. DOI: 10.3969/j.issn.1673 - 0364. 2023. 03. 001.

K, Le, Blanc, et al. Immunomodulation by mesenchymal stem cells and clinical experience [J]. Journal of Internal Medicine, 2007.DOI: 10.1111/j.1365-2796. 2007. 01844. x.

Peng FL, Chaofu Li, Shi B. Application of the nanovesicle delivery system in cardiovascular diseases. [J]. Chinese Journal of Tissue Engineering Research, 2023, 27 (30): 4862 - 4868.

Seluk. ztürk, Elin A E, Koca A, et al. Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives [J]. Stem cell reviews and reports, 2021, 17(2): 390 - 410. DOI:10.1007/s12015 - 020 - 10029 - 2.

Liu DY, Wang XY, Wang L, et al. Mesenchymal stem cell-derived exosome transplantation for ischemic heart disease [J]. Chinese Journal of Tissue Engineering Research, 2023, 27 (15): 2435 - 2442.

Zhen K, Wei XJ, Zhang HC. Research status of exosomes in the treatment of cardiovascular diseases [J]. Journal of Air Force Medical University, 2023, 44 (8): 770 - 774. DOI: 10.13276/j. issn.2097 - 1656. 2023. 08. 018.

Yue FF, Song L, Wang XB, Wang L. Application and effect of extracellular vesicles in cardiac repair after myocardial infarction [J]. Chinese Journal of Tissue Engineering Research, 2023, 27 (10): 1610 - 1617.

Sun, F.; Sun, Y.; Wu, F.; Xu, W.; Qian, H. Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapy for Diabetes Mellitus and Diabetic Complications. Pharmaceutics 2022, 14, 2208.

Wu Q, Wang J, Tan W L W, et al. Extracellular vesicles from human embryonic stem cell-derived cardiovascular progenitor cells promote cardiac infarct healing through reducing cardiomyocyte death and promoting angiogenesis [J]. Cell Death & Disease [2023-08-27]. DOI: 10.1038/s41419-020-2508-y.

Wang L, Wang D, Ye Z, Xu J. Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications. Adv Sci (Weinh). 2023 Jun; 10 (17): e2300552. doi: 10.1002/advs.202300552. Epub 2023 Apr 20.

Xuan L, Fu D, Zhen D, et al. Extracellular vesicles derived from human bone marrow mesenchymal stem cells protect rats against acute myocardial infarction-induced heart failure [J]. Cell and Tissue Research, 2022, 389 (1): 23 - 40. DOI: 10.1007/s00441 - 022 - 03612 - 1.

Bai X, Zhang X, Li Z, et al. Platelet-derived extracellular vesicles encapsulate microRNA-34c-5p to ameliorate inflammatory response of coronary artery endothelial cells via PODXL-mediated P38 MAPK signaling pathway. Nutrition, Metabolism and Cardiovascular Diseases, 2022.

Jian M, Li C, Xiang Z, et al. Mesenchymal stem cell-derived exosomal miR-21a-5p promotes M2 macrophage polarization and reduces macrophage infiltration to attenuate atherosclerosis [J]. Acta Biochimica et Biophysica Sinica (9): 9 [2023-08-27]. DOI: 10.1093/abbs/gmab102.

Li XC. Vigagliptin improves autophagy through miR-21a-5p/PTEN/Akt/mTOR pathway to prevent diabetes cardiomyopathy[D]. Tianjin: Tianjin Medical University, 2019.

Cheng G, Labedz-Maslowska A, Berdecka D, et al. Abstract 16673: Intramyocardial Injection of MSC-derived Extracellular Vesicles Confers Superior Cardiac Repair After a Repercussed Myocardial Infarction [J]. Circulation, 2015, 132 (suppl_3). DOI: 10.1161/circ.132.suppl_3.16673.

Chen B, Luo L, Wei X, et al.M1 Bone Marrow-Derived Macrophage-Derived Extracellular Vesicles Inhibit Angiogenesis and Myocardial Regeneration Following Myocardial Infarction via the MALAT1/MicroRNA-25-3p/CDC42 Axis. [J]. Hindawi Limited, 2021.DOI:10.1155/2021/9959746.

Khandagale A, Lindahl B, Lind S B, et al. Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death [J]. Current research in translational medicine, 2022, 70 (2): 103323. DOI: 10.1016/j.retram. 2021. 103323.

Yu B, Kim H W, Gong M, et al. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardio protection [J]. International journal of cardiology, 2015, 182: 349 - 60. DOI: 10.1016/j.ijcard.2014.12.043.

Cheng G, Labedz-Maslowska A, Berdecka D, et al. Abstract 16673: Intramyocardial Injection of MSC-derived Extracellular Vesicles Confers Superior Cardiac Repair After a Reperfused Myocardial Infarction [J]. Circulation, 2015, 132 (suppl_3). DOI: 10.1161/circ.132.suppl_3.16673.

Wang N, Chen C, Yang D, et al. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis [J]. Biochimica et Biophysical Acta (BBA) - Molecular Basis of Disease, 2017. DOI: 10.1016/j.bbadis. 2017. 02. 023.

Injection-Free Delivery of MSC-Derived Extracellular Vesicles for Myocardial Infarction Therapeutics [J]. Advanced Healthcare Materials, 2021.DOI:10.1002/adhm.202100312.

Monguió-Tortajada M, Prat-Vidal C, Martínez-Falguera D, Teis A, Soler-Botija C, Courageux Y, Munizaga-Larroudé M, Moron-Font M, Bayes-Genis A, Borràs FE, Roura S, Gálvez-Montón C. Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model. Theranostics. 2022 Jun 6; 12 (10): 4656 - 4670. doi: 10.7150/thno.72289.

Ning Y, Huang P, Chen G, Xiong Y, Gong Z, Wu C, Xu J, Jiang W, Li X, Tang R, Zhang L, Hu M, Xu J, Xu J, Qian H, Jin C, Yang Y. Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway. BMC Med. 2023 Mar 16; 21 (1): 96. doi: 10.1186/s12916 - 023 - 02778 - x.